Dr. Jack Cush reviews the news, journal reports and regulatory approvals from this past week on RheumNow.com
--------
18:16
An Epidural Letdown (4.4.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com.
**Correction: a Tweet from 3/18 podcast, had incorrect information. Late Breaking abstract from 2025 Amer. Acad. Dermatology (AAD) on the Phase 3 ICONIC-LEAD study showed J&J's oral IL-23 inhibitor (icotrokinra) was superior to PLACEBO (not deucravacitinib as reported) in skin clearance (65% vs 8%) & PASI90 (50% v 4%) at Wk 16 (NOT 15) in 684 moderate-to-severe plaque PsO pts https://buff.ly/dMbTbML
--------
21:35
Biomarkers in RA
Rheumatologist Dr. Walter Maksymowych discusses the role of biomarkers in RA care, with a focus on 14-3-3eta as a modifiable marker for diagnosis and monitoring disease progression.
--------
11:29
Cancer Survival with TNF Inhibitors (3.28.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com
--------
22:45
ERA, APPs, & Alpha GAL (3.21.2025)
Dr. Jack Cush reviews the news and journal reports from this past week on RheumNow.com. Listen in for 2 new case questions - Ask Cush Anything.
Colombia